HLHsiang-Hsi Ling

Hsiang-Hsi Ling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hsiang-Hsi Ling has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Cheng-Wei Lin

    Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan

    3 shared publications
  • Chih-Chia Kuo

    Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

    2 shared publications
  • Aaron D. Viny

    Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY

    1 shared publication
  • Ajay K. Saw

    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    1 shared publication
  • Bo-Xing Lin

    Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan

    1 shared publication
  • Cheng-Hsun Chen

    Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

    1 shared publication

Latest Publications

  • Mediator subunit MED4 enforces metastatic dormancy in breast cancer

    by Seongyeon S. Bae, Hsiang-Hsi Ling, Jiankang Zhang, Yi Chen, Hong Chen, Dhiraj Kumar, Ajay K. Saw, Kunal Rai, Aaron D. Viny, Ronald A. DePinho, et al.

    Long-term survival in breast cancer is often limited by metastatic recurrence arising from disseminated cancer cells that persist in a dormant state. The mechanisms that enable these dormant cells to survive and subsequently reawaken remain incompletely understood. Here an unbiased genome-scale genetic screen identified Med4 as a cancer cell-intrinsic gatekeeper in metastatic reactivation. Correspondingly, MED4 haploinsufficiency was found to be prevalent in metastatic breast cancer and associated with poorer clinical outcomes. Syngeneic mouse metastasis models revealed that MED4 enforces metastatic dormancy. Mechanistically, and unexpectedly given the canonical role of the Mediator complex in transcriptional activation, MED4 suppresses enhancer priming (H3K4me1) and activation (H3K27ac). Loss of a single Med4 allele disrupts enhancer poise, leading to extracellular matrix remodelling and integrin-mediated mechanotransduction programmes that ultimately drive metastatic outgrowth. Together, these findings establish MED4 as a key regulator of breast cancer cell dormancy and nominate MED4 haploinsufficiency as a potential predictive biomarker for patients at high risk of metastatic relapse.


  • Open Access

    Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit

    by Chih-Chia Kuo, Hsiang-Hsi Ling, Ming-Chen Chiang, Chu-Hung Chung, Wen-Ying Lee, Cheng-Ying Chu, Yu-Chih Wu, Cheng-Hsun Chen, Yi-Wen Lai, I-Lin Tsai, et al.

    Rationale: Cancer cells reprogram cellular metabolism to fulfill their needs for rapid growth and metastasis. However, the mechanism controlling this reprogramming is poorly understood. We searched for upregulated signaling in metastatic colorectal cancer and investigated the mechanism by which Glut3 promotes tumor metastasis.


  • Activation of fibroblasts by nicotine promotes the epithelial‐mesenchymal transition and motility of breast cancer cells

    by Pin‐Cyuan Chen, Wen‐Ying Lee, Hsiang‐Hsi Ling, Chia‐Hsiung Cheng, Ku‐Chung Chen, Cheng‐Wei Lin

    The tumor microenvironment plays an important role in tumor initiation and progression. It is well documented that nicotine participates in cigarette smoking‐related malignancies. Previous studies focused on the effects of nicotine on tumor cells; however, the role of the microenvironment in nicotine‐mediated tumorigenesis is poorly understood. Herein, we investigated the effect and molecular mechanism of nicotine on fibroblasts and its contribution to breast cancer. We found that nicotine induced the epithelial‐mesenchymal transition (EMT) of breast cancer cells and promoted activation of fibroblasts. Interestingly, conditioned medium from nicotine‐activated fibroblasts (Nic–CM) had a greater impact on promoting the EMT and migratory capability toward cancer cells than did treatment with nicotine alone. Production of connective tissue growth factor (CTGF) and transforming growth factor (TGF)‐β by nicotine‐treated fibroblasts was demonstrated to be crucial for promoting the EMT and cancer cell migration, and blocking of CTGF and TGF‐β in Nic‐CM‐suppressed tumor motility. Moreover, nicotine induced expressions of CTGF, and TGF‐β in fibroblasts as identified through α7 nicotinic acetylcholine receptor (nAChR)‐dependent activation of the AKT/TAZ signaling mechanism. Together, our data showed for the first time that activation of fibroblasts is largely responsible for accelerating smoking‐mediated breast cancer progression.


  • Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer

    by Hsiang-Hsi Ling, Chih-Chia Kuo, Bo-Xing Lin, Yen-Hua Huang, Cheng-Wei Lin